Navigation Links
Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial

per protocol clinical cure rate compared to Biaxin(R) in CAP (cethromycin 91.5% (205/224) compared to Biaxin(R) 95.9% (212/221) [-9.1, +0.3], p=0.0775). Cethromycin's achievement of a 91.5% clinical cure rate is consistent with its Phase 2 clinical trial results at the same 300 mg once-daily dose for CAP. The comparator drug, Biaxin(R), achieved a cure rate higher than the historical rate observed in any reported Biaxin(R) CAP clinical trials to date.

Cethromycin also achieved positive safety results in the study. Cethromycin demonstrated an improved safety profile when compared with the results seen in its previous clinical trials. Additionally, the incidence of adverse events was not statistically different between cethromycin and Biaxin(R). The most common adverse events reported in patients receiving cethromycin were mild-to-moderate diarrhea (cethromycin 5.0%, Biaxin(R) 4.6%), headache (cethromycin 3.1%, Biaxin(R) 6.5%), nausea (cethromycin 2.7%, Biaxin(R) 3.8%), vomiting (cethromycin 2.7%, Biaxin(R) 1.5%), abdominal pain (cethromycin 1.5%, Biaxin(R) 3.1%) and taste disturbance (cethromycin 11.1%, Biaxin(R) 6.2%). No drug-related serious adverse events were observed in any study subject. Liver function tests and electrocardiogram monitoring demonstrated no significant differences between subjects receiving cethromycin and subjects receiving Biaxin(R), consistent with the hepatic and cardiac side effect profile reported in cethromycin's previous clinical trials.

Cethromycin is not approved as a treatment for CAP, and data from this analysis have not been reviewed by the FDA. No further details of the clinical study will be available until all data analyses are complete and results are presented in a public, scientific forum.

Program Design

The Phase 3 CAP clinical trial program is comprised of two randomized, well controlled, double-blind, multi-center, multi-national, comparator trials designed to assess the safety and effectiveness
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
2. Cethromycin Shown Effective Against Anthrax in Study
3. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
4. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
7. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
8. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
9. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
Post Your Comments:
(Date:4/27/2015)... 2015 Harwood Feffer LLP ( www.hfesq.com ) ... of Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") (NASDAQ: ... its fiduciary duties to shareholders. On April ... results from its first Phase 3 registration trial of ... in the trial, Rhopressa failed to meet its primary ...
(Date:4/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/t2mvbz/endoscopy_global ... "Endoscopy Global Market - Forecast to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769) , , ,The global endoscopy market is ... growing at around 7.0% CAGR from 2014 to ... are aging population, increase in cancer, diabetes, and ...
(Date:4/27/2015)... April 27, 2015 Vermillion, Inc. ... gynecologic disease, announced today it will report ... market close on Monday, May 11, 2015, ... webcast at 4:30pm Eastern.Conference Call & Webcast: ... Pacific Domestic: , 888-556-4997International: , 719-457-2628Conference ID: ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3
... Va., Nov. 10, 2011 Primary healthcare distributors continue ... navigating economic, regulatory and business climate challenges in the ... in the U.S. Healthcare Industry released by the ... the non-profit research foundation of the Healthcare Distribution Management ...
... SKILLMAN, N.J., Nov. 10, 2011 ConvaTec Healthcare today announced that ... 15, 2011. David Johnson, CEO and George Kegler, CFO will host ... telephone. Questions and answers will follow. To participate ... 701-0354. To participate in the conference internationally, dial ...
Cached Medicine Technology:Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 2Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 3Pharmaceutical Distributors Continue to Deliver Operational Efficiencies and Value to U.S. Healthcare System Amidst Economic and Regulatory Challenges 4ConvaTec Healthcare Announces 2011 Third Quarter Earnings Call 2
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable ... and Fashion Show from 10:30 a.m. to noon on ... 2626 W. 63rd St. in Chicago, serves low-income older ... to maintain their independence. , “Mothers, grandmothers, godmothers and ... Day Brunch,” said Director of Marketing Elizabeth Clippard. , ...
(Date:4/27/2015)... Church, VA (PRWEB) April 28, 2015 ... Works, **Presented by FDAnews and Ombu Enterprises**, June 16-17, ... If an FDA inspector came to a facility today, ... , If the answer is "maybe" or "no" ... Ombu Enterprises and FDAnews have a solution. , ...
(Date:4/27/2015)... 2015 How to Implement UDI:, Lessons ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/HowToImplementUDI ... of regulatory restraint, there’s plenty of time to get ... again. UDI deadlines are coming fast for all devicemakers ... Don’t delay, even if it seems there’s no rush. ...
(Date:4/27/2015)... April 28, 2015 Healthcare marketing ... paper called “Website Anatomy 101.” Available ... the necessary design elements for a successful hospital ... responsive design, user experience, search results and lead ... of a well-designed website on patient volume and ...
(Date:4/27/2015)... 2015 Women may have a more ... to a new study published online in the journal ... injury (MTBI), is a common medical problem affecting cognitive ... , In most cases, patients who experience MTBI will ... percent of MTBI patients will continue to experience persistent ...
Breaking Medicine News(10 mins):Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 2Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 3Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3
... 3 America,s oldest voluntary health organization is led ... Elected National Board Chair, after more than a decade ... successfully steered the American Lung Association to tackle key ... of his chairmanship has been to build on the ...
... variation in exposure, depending on several factors, , , TUESDAY, ... widely among people who undergo computed tomography (CT) scans, ... in the Feb. 4 issue of the Journal ... after the American Heart Association urged that CT scans ...
... for Southeastern Michigan Screens Patients DETROIT, Feb. 3 ... Saturday, February 7, over 300 children from the Detroit ... of the American Dental Association,s seventh annual "Give Kids ... their services that day to children who, because of ...
... Reinforce Commitment to Safety Net Partnerships and Quality ... Kaiser Permanente announced today that ... totaling approximately $43 million in the fourth quarter ... Community Benefit grants in the fourth quarter focused ...
... Feb. 3 Nearly three out ... insurance should cover the cost of addiction treatment ... their own health insurance would pay for substance ... Toward Addiction Survey" from Hazelden, the national nonprofit ...
... NASHVILLE, Tenn., Feb. 3 Healthcare Realty Trust,Incorporated (NYSE: ... cash dividend for the,quarter ended December 31, 2008. ... payable on March 5, 2009 to shareholders of record ... Realty Trust is a real estate investment trust that ...
Cached Medicine News:Health News:Maryland Lawyer Steve Nolan Advocates for Lung Health as National Board Chair of the American Lung Association 2Health News:Radiation From CT Scans Not Always the Same 2Health News:Radiation From CT Scans Not Always the Same 3Health News:Area Dentists, University of Detroit Mercy Team Up to Provide Free Dental Care to Low-Income, Uninsured Detroit-Area Children on Saturday, February 7 2Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 2Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 3Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 4Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 3Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: